ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Minoxidil

Also written as “Minoxidil Tablets”, “minoxidil + finasteride” and “5% minoxidil foam”.

Its studies are mostly in Alopecia · Hypotrichosis, led by 9 companies.

Drug pageMinoxidil: every studyMany companies study it; this page follows only the 13 they lead. All 40 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since May 8, 202313 company-led studies, 3 open or runningNext primary completion: Oct 30, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Aneira Pharmaits history only21 open or runningphase 1since May 8, 2023Mar 17, 2023none ahead
Galderma Group20 open or runningno phasesince May 29, 2015May 29, 2015none ahead
Industrial Farmacéutica Cantabriaits history only21 open or runningphase 3since May 25, 2023May 25, 2023none ahead
Johnson & Johnsonits history only20 open or runningphase 3since Sep 8, 2005Sep 8, 2005none ahead
3SBioits history only10 open or runningphase 3since Jul 15, 2025Jul 15, 2025none ahead
Beijing Dayspring Pharmaceutical Technologyits history only10 open or runningphase 2since Jul 1, 2025Jul 1, 2025none ahead
Eurofarma Laboratoriosits history only11 open or runningphase 3since Apr 8, 2026Apr 8, 2026Oct 30, 2028phase 3 · NCT07529977
Maja Kovacevic, MDits history only10 open or runningno phasesince Jun 25, 2015Jun 25, 2015none ahead
Samson Clinical Operations Ptyits history only10 open or runningphase 3since Apr 6, 2025Apr 6, 2025none ahead

Also a collaborator on its studies: Bioskin and Astrum CRO, S.L.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Galderma Group only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 29, 2015First studies: 2 no phase studies in AlopeciaFirst studyNCT02460497, NCT02460289

TargetBeta

“Sulfonylurea receptor 2, Kir6.2 opener”ChEMBL 37, by rule

Studies

All 2 Galderma Group leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02460497Alopecia · United States–CompletedSep 19, 201561
NCT02460289Alopecia · United States–CompletedNov 201563

How it is read

Names in the registry

  • “Minoxidil Tablets”, 2 entries
  • “Minoxidil”, 2 entries
  • “minoxidil + finasteride”, 2 entries
  • “5% minoxidil foam”, 1 entry
  • “Minoxidil oral solution”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.